Ryvu Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of RVU?
Owner Type	Number of Shares	Ownership Percentage
Public Companies	1,917,437	8.29%
General Public	3,486,547	15.1%
Individual Insiders	5,503,574	23.8%
Institutions	12,212,590	52.8%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 83.65% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
17.4%	Pawel Przewiezlikowski	4,016,985	zł129.1m	0%	no data
9.22%	PTE Allianz Polska SA	2,132,000	zł68.5m	0%	0.11%
8.29%	BioNTech SE	1,917,437	zł61.6m	0%	no data
8.26%	Towarzystwo Funduszy Inwestycyjnych Allianz Polska S.A.	1,910,236	zł61.4m	0%	1.31%
8.22%	Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A.	1,900,000	zł61.1m	0%	0.1%
5.54%	Forum Towarzystwo Funduszy Inwestycyjnych S.A.	1,279,738	zł41.1m	0%	5.52%
4.67%	Powszechne Towarzystwo Emerytalne PZU SA	1,080,308	zł34.7m	2,490%	0.12%
4.15%	Norges Bank Investment Management	960,477	zł30.9m	0%	no data
3.57%	Boguslaw Sieczkowski	825,348	zł26.5m	0%	no data
1.94%	Goldman Sachs Asset Management, L.P.	448,717	zł14.4m	0%	no data
1.77%	UNIQA Österreich Versicherungen AG, Asset Management Arm	410,017	zł13.2m	0%	0.1%
1.46%	Generali Powszechne Towarzystwo Emerytalne S A	337,401	zł10.8m	0%	0.04%
1.33%	Towarzystwo Funduszy Inwestycyjnych PZU SA	306,678	zł9.9m	0%	0.12%
1.27%	GAMMA PKO Towarzystwo Funduszy Inwestycyjnych SA	292,871	zł9.4m	0%	0.08%
1.24%	Aegon Asset Management UK Plc	287,104	zł9.2m	0%	0.01%
1.16%	Krzysztof Brzózka	267,321	zł8.6m	0%	no data
0.79%	AXA Towarzystwo Funduszy Inwestycyjnych SA	181,984	zł5.9m	0%	0.3%
0.68%	Franklin Resources, Inc.	156,312	zł5.0m	0%	no data
0.54%	Pioneer Pekao Towarzystwo Funduszy Inwestycyjnych S.A	125,743	zł4.0m	0%	0.13%
0.52%	Rafal Chwast	121,115	zł3.9m	0%	no data
0.51%	Skarbiec TFI S.A.	117,913	zł3.8m	0%	0.14%
0.4%	Tadeusz Wesolowski	92,975	zł3.0m	0%	no data
0.26%	Millennium TFI S.A.	61,056	zł2.0m	0%	0.24%
0.25%	Vatnak Vat-Ho	57,000	zł1.8m	0%	no data
0.23%	Union Investment TFI S.A	53,359	zł1.7m	0%	0.09%

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/08 05:42
End of Day Share Price	2025/05/08 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ryvu Therapeutics S.A. is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Beata Szparaga-Wasniewska	Biuro maklerskie mBanku
Mateusz Krupa	Biuro maklerskie mBanku
Jonas Peciulis	Edison Investment Research